An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015

Background: A quadrivalent human papillomavirus (HPV4) type 6/11/16/18 vaccine (GARDASIL/SILGARD®) has been licensed in many countries around the world for the prevention of cervical, vulvar, vaginal, and anal cancers and precancers, as well as external genital warts causally related to HPV types 6/...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2015

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/22776

Acceso en línea:

https://doi.org/10.1097/INF.0000000000000793
https://repository.urosario.edu.co/handle/10336/22776

Palabra clave:

Wart virus vaccine
Wart virus vaccine
Anaphylaxis
Anus cancer
Autoimmune disease
Cerebrovascular accident
Clinical protocol
Clinical trial (topic)
Drug safety
Drug surveillance program
Faintness
Genital system
Guillain Barre syndrome
Human
Human immunodeficiency virus infected patient
Incidence
Licensing
Pharmacoepidemiology
Precancer
Pregnant woman
Priority journal
Public health
Review
Skin infection
Systemic lupus erythematosus
Uterine cervix cancer
Vaccination
Vagina cancer
Venous thromboembolism
Verruca vulgaris
Vulva cancer
Adolescent
Adult
Child
Drug-Related Side Effects and Adverse Reactions
Female
Male
Middle aged
Papillomavirus Infections
Pathology
Postmarketing surveillance
Pregnancy
Young adult
Adolescent
Adult
Child
Drug-Related Side Effects and Adverse Reactions
Female
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Humans
Male
Middle Aged
Papillomavirus Infections
Pregnancy
Young Adult
Gardasil
Human papillomavirus
Safety
Surveillance
Vaccine
Postmarketing
Product Surveillance

Rights

License

Abierto (Texto Completo)